entertainment -WSS

entertainment

author：Wikipedia 2025-09-28 00:53:09 - browse：44788

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： UnitedHealth’s board chair also owns a personal investment firm

hotspot

WSS

Pharma companies must ensure equitable access to obesity drugs

STAT Summit: GSK CEO on pharma giant's new direction

HHS leader on health, climate change and biopharma emissions

NIH confirmation hearing shows politicization of research

Health care court cases: Humana, Sutter, Novant

California wildfire smoke linked to 52,000 early deaths, study says

knowledge

entertainment

focus

In Memoriam: Notable people who died in 2023

Coercive sterilizations revealed by STAT prompt outrage

Psychedelics group wrestles with new pharma identity

Senate committee scrutinizes Medicare Advantage brokers

Virginia high school admissions case could be legal follow

Teladoc has a new CEO, but challenges remain the same

Jerome Adams on the need for new antivirals for Covid

Senate committee scrutinizes Medicare Advantage brokers

In Memoriam: Notable people who died in 2023

Study: Why relieving medical debt did not improve financial outcomes

leisure time

Researchers explore possible ties between long Covid, menopause

STAT Summit: Biotech founders on deal

Hospital price transparency does save money, advocate argues

Researchers explore possible ties between long Covid, menopause

The EU Joint Clinical Assessment needs to live up to its promise

NIH confirmation hearing shows politicization of research

hotspot

Wikipedia

explore

Wikipedia